elranatamab + lenalidomide + dexamethasone

Elranatamab + lenalidomide + dexamethasone is a combination regimen under clinical investigation for the treatment of multiple myeloma, particularly in patients who are newly diagnosed and ineligible for transplant. Elranatamab is a humanized bispecific monoclonal antibody that targets B cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, thereby redirecting T cells to kill malignant plasma cells. Lenalidomide is an immunomodulatory small molecule that exerts anti-myeloma effects through direct tumoricidal activity, immune modulation, and inhibition of angiogenesis. Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties commonly used as part of multiple myeloma regimens. This combination aims to enhance anti-myeloma efficacy by leveraging complementary mechanisms: targeted immune cell engagement by elranatamab, tumor microenvironment modulation by lenalidomide, and broad immunosuppression/anti-tumor effects from dexamethasone[2][4][6].

Brand names

ELREXFIO (elranatamab)Revlimid (lenalidomide)Decadron (dexamethasone)